FY2028 Earnings Estimate for Scholar Rock Issued By Wedbush

Scholar Rock Holding Co. (NASDAQ:SRRK) – Stock analysts at Wedbush boosted their FY2028 earnings per share (EPS) estimates for Scholar Rock in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.39 for the year, up from their prior estimate of $0.33. Wedbush has a “Outperform” rating and a $37.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.37) per share.

Other analysts also recently issued research reports about the stock. HC Wainwright boosted their price objective on shares of Scholar Rock from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday. BMO Capital Markets upped their price target on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, October 14th. Finally, Piper Sandler upped their target price on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $34.00.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $26.49 on Thursday. The company has a quick ratio of 6.04, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $35.38. The firm’s fifty day simple moving average is $20.61 and its 200-day simple moving average is $13.61. The stock has a market cap of $2.48 billion, a PE ratio of -11.27 and a beta of 0.47.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds have recently modified their holdings of the stock. Clearbridge Investments LLC purchased a new position in shares of Scholar Rock in the 2nd quarter worth $6,223,000. Candriam S.C.A. purchased a new position in Scholar Rock in the second quarter valued at approximately $6,201,000. Fisher Asset Management LLC raised its stake in shares of Scholar Rock by 593.6% in the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock valued at $5,879,000 after acquiring an additional 628,186 shares during the period. Millennium Management LLC lifted its stake in shares of Scholar Rock by 159.2% during the second quarter. Millennium Management LLC now owns 925,584 shares of the company’s stock worth $7,710,000 after purchasing an additional 568,512 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Scholar Rock by 1,051.3% in the second quarter. Marshall Wace LLP now owns 487,285 shares of the company’s stock worth $4,059,000 after buying an additional 444,961 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Scholar Rock

In related news, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the transaction, the chief financial officer now directly owns 161,088 shares in the company, valued at approximately $4,278,497.28. This represents a 56.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.25, for a total value of $34,389,605.25. Following the completion of the sale, the director now owns 5,612,896 shares of the company’s stock, valued at $164,177,208. This trade represents a 17.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,413,889 shares of company stock valued at $40,652,551 over the last quarter. Insiders own 19.20% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.